Long-term outcomes of transrectal high- intensity focused ultrasound for localized prostate cancer

Abstract

  We evaluated the long-term outcomes of transrectal high-intensity focused ultrasound（HIFU）for patients with localized prostate cancer（T1-T2）. Two hundred two patients（low 52, intermediate 94, high risk 56）were treated using the Sonablate 500^® and followed for over 12 months. Recurrence was judged using Phoenix definition, positive histological findings. In 12-137 months follow-up, no patients was died by prostate cancer. Of the 198 patients who underwent the histological examinations of the prostate in 6 months or later after HIFU, 20 were positive for cancer cells. The 5-year recurrent free survival rate was 95%, 82% and 60% in the low-, intermediate- and high-risk, respectively. There were no major postoperative complications, but dysuria（48 cases）, incontinence（22 cases,）and urethral stricture（13 cases）occurred during follow-up. HIFU is safe, repeatable and effective, particularly for low and intermediate risk group, and should be considered as an option for localized prostate cancer.